NCT03649997View on ClinicalTrials.gov

A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions
Healthy
Interventions
DRUG

JNJ-61393215

Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

DRUG

Placebo

Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.

DRUG

JNJ-61393215

Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.

Trial Locations (1)

NZ 9728

PRA Health Sciences, Groningen

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03649997 - A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants | Biotech Hunter | Biotech Hunter